489 related articles for article (PubMed ID: 25702645)
1. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
[TBL] [Abstract][Full Text] [Related]
2. Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient.
Pizzuti L; Sergi D; Barba M; Vici P
Tumori; 2013; 99(3):e127-30. PubMed ID: 24158082
[TBL] [Abstract][Full Text] [Related]
3. Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.
Carli P; Militello L; Miolo GM; Quitadamo D; Lombardi D; Torrisi E; Scalone S; Crivellari D; Spazzapan S
Tumori; 2014; 100(6):605-11. PubMed ID: 25688493
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
7. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
[TBL] [Abstract][Full Text] [Related]
9. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement.
Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V
Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803
[TBL] [Abstract][Full Text] [Related]
10. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available.
Bianchi GV; Duca M; Sica L; Mariani G
Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801
[TBL] [Abstract][Full Text] [Related]
11. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Schwartzberg LS; Wang G; Somer BG; Blakely LJ; Wheeler BM; Walker MS; Stepanski EJ; Houts AC
Clin Breast Cancer; 2014 Feb; 14(1):13-9. PubMed ID: 24268206
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.
Crivellari D; Spazzapan S; Lombardi D; Militello L; Torrisi E; Russo AE; Sorio R; Talamini R; Miolo G; Carli P; Veronesi A
Tumori; 2012; 98(1):33-8. PubMed ID: 22495699
[TBL] [Abstract][Full Text] [Related]
16. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab and vinorelbine as highly effective and safe therapy for HER-2-overexpressing metastatic breast cancer. A single institution experience.
Di Lauro V; Murrone A; Bidoli E; Magri MD; Crivellari D; Veronesi A
Tumori; 2008; 94(4):464-8. PubMed ID: 18822679
[TBL] [Abstract][Full Text] [Related]
18. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer.
Di Seri M; De Sanctis R; Quadrini S; Adua D; Stumbo L; Del Signore E; Gori B; Grassi P; Basile ML; Longo F
J Chemother; 2011 Apr; 23(2):110-3. PubMed ID: 21571629
[TBL] [Abstract][Full Text] [Related]
20. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
Tawfik H; Rostom Y; Elghazaly H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
